Nanoparticle Drug Delivery System
GPTKB entity
Properties (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:canBe |
Antibodies
Nucleic Acids Chemotherapeutic_Agents |
| gptkbp:enhances |
Therapeutic_Efficacy
|
| gptkbp:hasRelatedPatent |
Targeted Therapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nanoparticle Drug Delivery System
|
| gptkbp:improves |
Bioavailability
|
| gptkbp:isAssociatedWith |
Personalized Medicine
Controlled Release Targeted Drug Delivery Theranostics |
| gptkbp:isChallengedBy |
Regulatory Hurdles
Manufacturing Complexity Stability Issues Cost of Production |
| gptkbp:isCharacterizedBy |
Size Range
Drug Loading Capacity Release Profile Surface Modifications |
| gptkbp:isEvaluatedBy |
Clinical Trials
In Vitro Studies In_Vivo_Studies |
| gptkbp:isMarketedAs |
Startups
Pharmaceutical Firms Biotech_Firms |
| gptkbp:isPromotedBy |
Biotechnology
Nanotechnology Pharmaceutical Industry |
| gptkbp:isRegulatedBy |
gptkb:FDA
EMA |
| gptkbp:isStudiedIn |
Biomedical Engineering
Materials Science Pharmacology Nanomedicine |
| gptkbp:isSubjectTo |
Ethical Considerations
Clinical Guidelines Patent Protection Intellectual_Property_Laws |
| gptkbp:isUsedFor |
Polymers
Lipids Inorganic Materials |
| gptkbp:isUsedIn |
Vaccine Development
Cancer Treatment Gene Therapy |
| gptkbp:isVisitedBy |
Research Institutions
Universities Pharmaceutical Companies |
| gptkbp:reduces |
Side Effects
|
| gptkbp:uses |
Nanoparticles
|